Objectives Elevated liver enzyme concentrations in blood are indicative of liver diseases and may provide an early signal for being at risk for other chronic diseases. Our study aimed to assess the ...

Pain or discomfort on the upper right side of the abdomen just below the ribs, is also a warning sign of NAFLD. Since the liver is located here, the pain is felt as a dull or aching sensation, which ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Fatty liver impacts heart health. Doctor Cyriac Abby Philips suggests simple fitness tests. The One-Minute Sit-to-Stand Test ...

The Fantastic Four: First Steps director Matt Shakman has commented on whether Robert Downey Jr's Doctor Doom will make an appearance in the upcoming movie, and seemingly confirmed the character ...

The most deadly yet underdiagnosed condition by doctors: Non-Alcoholic Fatty Liver Disease. 1 in 3 adults have it and it silently leads to cancer, diabetes, and early death. Here are the warning ...

Harvard and Stanford-trained liver specialist Dr Saurabh Sethi ranks 10 common foods on a scale of 1 to 10, based on how good they are for fatty liver.

Rising liver disease deaths in India show sex, age, and state patterns, highlighting potential links to alcohol and meat consumption.

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the rise in popularity of liver cleanses, often spurred by social media, and their questionable safety.“These liver cleanses vary in ...

First Steps has three committees: the governing board, which includes original stakeholders and representatives from the town and village, a financial committee and a publicity committee.

ProQR Therapeutics announces a Phase 1 trial of AX-0810 to evaluate safety and target engagement in cholestatic liver disease.